The MicroArray Quality Control (MAQC) Project: An FDA-led Effort Toward Personalized Medicine
*Leming Shi, FDA's National Center for Toxicological Research Keywords: MAQC, microarray quality control, predictive models, classifiers Microarrays provide a unique opportunity for advancing medical product development and personalized medicine through the identification and qualification of biomarkers of efficacy and safety. To address reliability concerns raised in publications about microarrays (e.g., Marshall E, Science 2004; 306: 630 and Michiels S et al., Lancet 2005; 365: 488), the FDA launched the MicroArray Quality Control (MAQC) project in 2005 (http://edkb.fda.gov/MAQC/). The MAQC-I evaluated the technical performance of different microarray platforms in identifying differentially expressed genes (http://www.nature.com/nbt/focus/maqc/) and the MAQC-II has been progressively working toward consensus on the “best practices” of developing and validating microarray-based predictive models for clinical and preclinical applications.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC